Biomea Fusion Inc. has announced updated preliminary clinical data from its ongoing Phase I COVALENT-103 trial of the covalent FLT3 inhibitor BMF-500, aimed at treating adults with relapsed or refractory acute leukemia. The findings will be presented in a poster presentation at the European Hematology Association 2025 Congress in Milan, Italy, on Saturday, June 14. The study involves 27 patients, with a focus on those with FLT3-mutant acute myeloid leukemia. Results indicate that 9 out of 11 efficacy-evaluable patients showed significant bone marrow blast reduction, with five achieving over 50% reduction. Biomea Fusion plans to explore strategic partnerships to further develop BMF-500 following the completion of this trial phase.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。